Bloomios, Inc. (BLMS)
OTCMKTS · Delayed Price · Currency is USD
0.0001
0.00 (0.00%)
At close: Dec 26, 2025
Bloomios Revenue
Bloomios had revenue of $682.04K in the quarter ending September 30, 2023, a decrease of -43.07%. This brings the company's revenue in the last twelve months to $8.23M, up 46.53% year-over-year. In the year 2022, Bloomios had annual revenue of $6.08M, down -28.43%.
Revenue (ttm)
8.23M
Revenue Growth
+46.53%
P/S Ratio
0.00
Revenue / Employee
n/a
Employees
n/a
Market Cap
6.79K
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2022 | 6.08M | -2.41M | -28.43% |
| Dec 31, 2021 | 8.49M | 7.18M | 545.11% |
| Dec 31, 2020 | 1.32M | - | - |
| Dec 31, 2019 | - | - | - |
| Jan 31, 2019 | - | - | - |
| Jan 31, 2007 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jan 31, 2006 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jan 31, 2005 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jan 31, 2004 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jan 31, 2003 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| American Oncology Network | 1.76B |
| Veradigm | 588.02M |
| Glass House Brands | 196.17M |
| Vaxart | 148.20M |
| Elite Pharmaceuticals | 122.89M |
| Silence Therapeutics | 25.83M |
| OpGen | 9.00M |
| Stem Cell Authority | 3.33M |
Bloomios News
- 2 years ago - Bloomios Appoints Kevin Henry as National Sales Director - PRNewsWire
- 2 years ago - Bloomios Reports Q1 2023 Revenue up 30% Sequentially and 84% Y/Y to $2.75 Million - PRNewsWire
- 3 years ago - Bloomios Appoints Industry Veteran, Joe Reid, as Chief Manufacturing Officer - PRNewsWire
- 3 years ago - Bloomios Completes $23.5 Million Acquisition of Leading Gummy Manufacturer - PRNewsWire
- 3 years ago - Upexi Announces Sale of Select CBD Assets for $23.5 Million - PRNewsWire
- 3 years ago - Bloomios To Present at The 2022 LD Micro Main Event October 25-27 - Newsfile Corp
- 3 years ago - Bloomios to Develop and Produce New Range of Private-Label Products Utilizing, Ashwagandha, Melatonin, Kratom, Lion's Mane, Valerian Root, Reishi Mushroom and other Natural Ingredients - PRNewsWire
- 3 years ago - Bloomios to Present at the 2022 LD Micro Invitational June 7-9 - PRNewsWire